Weight Management

Presented at the 2025 American Society for Metabolic and Bariatric Surgery Annual Meeting, June 15–19 in Washington, D.C., this study compared patient-reported eating-related outcomes following sleeve...

A retrospective cohort study found that patients on GLP-1 agonists had a lower risk of periprosthetic joint infection but a higher risk of periprosthetic fractures following total knee arthroplasty.

At the American Association of Clinical Endocrinology 2025 Annual Meeting, Jaime Almandoz, MD, MBA, FTOS, discussed the importance of continuing medical treatment for patients with obesity following...

At the American Association of Clinical Endocrinology 2025 Annual Meeting, Daniel Drucker, OC, MD, FRCPC, FRSC, FRS, discussed the evolving scope of GLP-1–based therapies, highlighting emerging molecules,...

A post hoc analysis of the SURMOUNT-1 trial reveals that cardiometabolic improvements achieved after 176 weeks of tirzepatide may diminish significantly within 17 weeks of treatment cessation, particularly...

A randomized phase 3 trial evaluated cebranopadol, a dual-NMR agonist, for postoperative pain after abdominoplasty and found reduced pain and opioid use. This study was presented on May 1, 2025, at the ASRA...

A recent presentation at the American College of Physicians Internal Medicine Meeting 2025 highlighted updated approaches to inpatient diabetes management.

A study presented at the American College of Cardiology's 74th Annual Scientific Session found that GLP-1RA use in patients with psoriasis was linked to a lower incidence of major adverse cardiovascular...

A real-world retrospective study found that adding GLP-1 receptor agonists to hormone therapy may reduce endometrial cancer risk in women with benign uterine or endometrial hyperplasia. This study was...

A randomized clinical trial found that while low-magnitude mechanical signals did not improve trabecular bone mineral density in adolescents with anorexia nervosa, it significantly increased tibial bone...